Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation.

ABSTRACT:

Objectives

Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment of MG is not broadly considered. Our objective is to report on the efficacy and safety of HSCT in refractory MG.

Methods

Twenty-one patients who underwent HSCT for MG were retrospectively reviewed. All patients had severe MG refractory to multiple therapies. Stem cells were mobilized with cyclophosphamide and granulocyte colony-stimulating factor. The grafts were depleted of immune cells by selecting CD34+ cells. HSCT conditioning consisted of high-dose cytoreductive therapy and anti-thymocyte globulin. The primary efficacy outcome was achieving clinically sta

SUBMITTER: Beland B 

PROVIDER: S-EPMC11752101 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature